NICE recommends hep C drugs Olysio and Sovaldi
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has given the go-ahead for two competing hepatitis C drugs to be reimbursed by the NHS; Janssen's Olysio (simeprevir) and Gilead's Sovaldi (sofosbuvir).